Brokerages Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) PT at $41.86

Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) have been given an average rating of “Buy” by the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average […]

Leave a Reply

Your email address will not be published.

Previous post Wall Street Zen Upgrades Atlassian (NASDAQ:TEAM) to Buy
Next post Ferguson FY2027 EPS Estimate Raised by William Blair